Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma.

Published

Journal Article

INTRODUCTION: Chronic liver disease due to viral hepatitis continues to be a major global health concern. Timely diagnosis and treatment will prevent cirrhosis, risk of hepatocellular carcinoma (HCC), and requirement for liver transplantation. Numerous serum biomarkers are available for viral hepatitis that are helpful in diagnosis, measuring severity, progression of disease, evaluating the best therapeutic options, and monitoring antiviral treatment response. Determining the clinical use of available diagnostic tests can be challenging for the health care provider. Areas covered: This review article attempts to summarize the established and emerging serological markers for diagnosis and managing viral hepatitis. The literature search was performed in February 2018 and included MEDLINE and Embase databases for recent relevant literature on biomarkers for viral hepatitis. Expert Commentary: Despite the discovery of several candidate biomarkers, translating these to clinical practice in viral hepatitis and HCC remains challenging. While limited availability of the new biomarkers in prevalent geographic areas and significant cost remain major obstacles, there have been exciting developments in this field. Understanding the detection limits and sensitivity of these markers and translating them into clinical use is important in management of viral hepatitis and complications of liver disease such as cirrhosis and hepatocellular cancer.

Full Text

Duke Authors

Cited Authors

  • Kotha, S; Neong, S; Patel, K

Published Date

  • August 2018

Published In

Volume / Issue

  • 18 / 8

Start / End Page

  • 713 - 722

PubMed ID

  • 30019978

Pubmed Central ID

  • 30019978

Electronic International Standard Serial Number (EISSN)

  • 1744-8352

Digital Object Identifier (DOI)

  • 10.1080/14737159.2018.1496020

Language

  • eng

Conference Location

  • England